JPRN-jRCT1080225198TerminatedPhase 1
Phase I Study of Combination Therapy with OBP-301 and Chemoradiotherapy in Patients with Locally Advanced Esophageal Cancer
Conditions
Trial Snapshot
- Phase
- Phase 1
- Status
- Terminated
- Enrollment
- 20
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- >= 20age old to ot applicable (—)
- Sex
- All
Inclusion Criteria
- •The patient was histologically diagnosed with esophageal cancer (squamous cell carcinoma, adenocarcinoma, etc.) by endoscopic biopsy of the primary esophageal lesion, and had a lesion capable of local injection.
- •- The center of esophageal lesions (primary lesion, intramural metastasis, intraepithelial extension) is located in the thoracic esophagus (8th edition of UICC-TNM). However, if the center of the lesion is more distal than the line 2 cm proximal to the esophagogastric junction (the lower end of the palisade vessels seen endoscopically or the upper edge of the gastric mucosal folds), it is not eligible. Esophageal lesions may be single or multiple.
- •- In the 8th edition of UICC-TNM, cT1N2-3,cT2-3N0-3 of adenocarcinoma and cT1N1-3,cT2-3N0-3 of squamous cell carcinoma without distant metastases on cervical-abdominal CT.
- •- ECOG Performance Status (PS) is 0 to 1.
- •- Radical esophagectomy is not indicated or refused by patient.
- •- Definitive chemoradiation is indicated.
Exclusion Criteria
- •- Patients with active double cancers that require treatment (synchronous double cancers and metachronous double cancers with a disease-free interval of less than 3 years).
- •However, carcinoma in situ, carcinoma of the pharynx, larynx, carcinoma of the skin, and carcinoma of the prostate that does not require treatment, which are not considered to affect prognosis, are not included in active double cancers. Also, a history of a pathologic stage cancer that has been completely resected with a 3-year relative survival of at least 95% or less is not included in the active double cancer.
- •- The chemotherapy was carried out for esophageal cancer in the past.
- •- If you have previously received radiotherapy for cervical, thoracic and upper abdominal lesions.
Investigators
Similar Trials
Completed
Phase 1
Phase I Study of Combination Therapy with OBP-301, Atezolizumab and chemoradiotherapy in Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck CancerHead and Neck CancerJPRN-jRCT2063200044Fujiwara Toshiyoshi23
Completed
Phase 2
Phase II Study of Combination Therapy with OBP-301 and Radiotherapy in Patients with Locally Advanced Esophageal Canceresophageal carcinomaJPRN-jRCT1080225033Oncolys BioPharma Inc.37
Completed
Phase 1
Phase I Study of Combination Therapy with OBP-301, Atezolizumab and Bevacizumab in Patients with Hepatocellular CarcinomaHepatocellular carcinomaJPRN-jRCT2033200223Doi Toshihiko4
Unknown
Phase 1
A Study of OBP-301 With Radiation Therapy in Patients With Esophageal CancerEsophageal CancerNCT03213054Oncolys BioPharma Inc12
Recruiting
Phase 1
Phase I/II trial of combined chemotherapy of Nab-paclitaxel, S-1, and Oxaliplatin for gastric cancer patients with peritoneal metastasis (NSOX study)gastric cancer with peritoneal metastasisJPRN-UMIN000030909Wakayama Medical University, School of Medicine35